CompletedPHASE1, PHASE2NCT03239392
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
Studying Aggressive NK-cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bioniz Therapeutics
- Principal Investigator
- Jonathan Brammer, MD, PhDOhio State University
- Intervention
- BNZ132-1-40(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2020
Study locations (4)
- City of Hope National Medical Center, Duarte, California, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- The James Cancer Center, Ohio State University, Columbus, Ohio, United States
- University of Virginia Cancer Center, Charlottesville, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03239392 on ClinicalTrials.govOther trials for Aggressive NK-cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06716658JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT05863234Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaHiroshima University Hospital
- RECRUITINGPHASE2NCT05941156Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell LeukemiaThe Affiliated Hospital of Xuzhou Medical University